Stifel raised the firm’s price target on Disc Medicine (IRON) to $111 from $110 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
- Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
- Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
- Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
- Disc Medicine price target lowered to $88 from $110 at Wedbush